Skip to main content

Featured

The Fed Decides Wednesday — Here's What It Means for Your Mortgage, the Loonie, and Your RRSP

  Monday, July 27, 2026 The U.S. Federal Reserve hands down its rate decision at 2 p.m. ET on July 29. For most Canadians it will feel like background noise. It isn't — here's the plain-language version of why it touches your mortgage, your cross-border spending, and whatever's sitting in your RRSP. The short version: Markets are pricing roughly a two-in-three chance the Fed holds its rate at 3.50%–3.75% on Wednesday. That's not the story. The story is that this is one of the least certain "sure thing" holds in years — and Chair Kevin Warsh's press conference at 2:30 p.m. ET could matter more than the decision itself. Why this meeting is different The Fed has held its benchmark rate steady at 3.50%–3.75% through every meeting so far in 2026. On paper, Wednesday should be more of the same. Under the hood, it's messier. Persistent inflation, running well above the Fed's 2% target for a fifth straight year, has kept a rate hike on the table. The oil-...
Post a Comment
Read more

article

Labels

Controversial Turkish Import Endangers Newborns in Alberta, Documents Reveal

 

Recent documents have raised alarming concerns over Alberta’s emergency importation of children’s pain medication from Turkey. Produced by Atabay Pharmaceuticals and sold under the brand name Parol Suspension, the drug is marketed at a concentration of 24 mg/ml—significantly lower than the 32 mg/ml concentration found in the standard, Canadian-authorized formulation.

Health experts and opposition critics warn that this altered concentration poses a twofold risk. First, the discrepancy could lead to dosing errors if parents and caregivers, accustomed to the standard formulation, misjudge the correct volume needed. Second, there are fears that the lower concentration may lead to the clogging of hospital feeding tubes—a critical concern for vulnerable newborns.

Alberta Blue Cross has informed pharmacists that Parol must be dispensed with enhanced caution, requiring additional education on its proper use. Critics argue that the rushed procurement—amounting to approximately $80 million—exemplifies a misstep in prioritizing political expedience over stringent safety protocols. With traditional supplies of children’s pain medications already in short supply, many worry that this controversial alternative might jeopardize the health of Alberta’s youngest patients.

Further review and tighter regulatory oversight are now being called for, as stakeholders demand that the province safeguard the well-being of newborns and ensure that emergency measures do not compromise pediatric care.

Labels:

Comments

Post a Comment